Introducing Mictamid®

A long lasting, 2.5% polyacrylamide hydrogel designed to restore continence in dogs with USMI.

    SAFE

    Bulking agent that achieves therapeutic effect without chronic inflammation or fibrosis.

    Non pharmaceutical, biocompatible hydrogel comprised of 97.5% water and 2.5% cross linked polyacrylamide.

    Homogenous, inert, non-degradable, non-migratory, and non-toxic.

    DURABLE

    Maintains volume long term.

    Designed for multi-year continence improvement.

    2.5% iPAAG permanently integrates into tissue and is not absorbed like other bulking products.

    EFFICACIOUS

    Strong veterinary clinical outcomes across treated species.

    Demonstrated improvement in continence outcomes in dogs with USMI based on veterinary clinical experience and early adopter data.

    Non-particulate, non-resorbable hydrogel designed for durable tissue bulking.

Early Clinical Experience in Canine USMI

Early evaluations demonstrate consistent improvements when correct volume andplacement are achieved.

  • Majority of treated dogs 
reached full continence.
  • Remaining dogs demonstrated 
meaningful improvement.
  • Consistent coaptation achieved 
with proper submucosal depth.
  • Low incidence of transient 
adverse events.

JD Foster, VMD, MS, DACVIM (SAIM), DACVCP, DACVNU

ACVNU Founding Member, Nephrologist-Urologist

“Mictamid represents a significant advancement in the management of USMI. When the hydrogel is delivered precisely into the submucosal plane, it provides a safe and highly effective means of achieving urethral coaptation to correct urinary incontinence.”

Standardized Injection Technique

  • Mictamid® is injected into the urethral submucosa under cystoscopic guidance.
  • A standardized two-series injection technique supports circumferential coaptation and reproducible results.
  • Four injections per series at 5, 7, 2, and 10 o’clock.
  • Foundational injection series approximately 2 cm from the bladder neck.
  • Reinforcing injection series approximately 2 cm distal to the foundational series.
  • Total target volume equals 5 mL.
  • Administered through a novel, proprietary delivery system designed specifically for canine urethral anatomy.
  • Key Advantages for Your Practice

    • Fast and cost-effective procedure performed under sedation.
    • Minimally invasive outpatient procedure.
    • Reduces or eliminates the need for lifelong medication.
    • Durable soft tissue bulking.
    • Proprietary delivery system designed for canine anatomy.
  • Training and Support

    • Wet labs in office.
    • Procedural videos coming soon.
    • Peer-to-peer case observation; live or virtual.

Discover how Mictamid® supports
long-term improvements in incontinence.

Discover how targeted urethral support can make a measurable difference.